EbM Kongress, March 2018

Non-drug treatments and the waste in research

Paul Glasziou

Centre for Research in Evidence-Based Practice Bond University <u>www.crebp.net.au</u>

Summary

• Effective Non-Drug treatments:

many developed and tested, but most are poorly described and little used

• Waste in Research:

over 85%, due to poor design, non-publication, and poor reporting





Know any breathing exercises?

GP patient:

Long term smoker with chronic obstructive airways disease has recently quit smoking.

Has tried medications but does not like any.

Asks: are any "breathing exercises" I can recommend?



19 Beaumont St, Oxford

What about didgeridoo playing?





Puhan M, et al. BMJ, 2006

Inadequate treatment descriptions Analysis of 80 studies in EBM journal

"Could you use this treatment with a patient tomorrow?"



Glasziou P, et al. BMJ 2008;336:1472-74

Handbook of Non-Drug Interventions

60 entries; 15 new / year Free access at <u>www.racgp.org.au/handi/</u> Indexed in PubMedHealth





<u>HANDI Committee</u> GPs, Occupational Therapist, Physiotherapist, Physician

and Raquel Newman (medical writer); Joanna Ong & Gisele Rocha (RACGP senior project officers)

Types of treatments in HANDI







Info My QuitBuddy Settings

DEVICES Nasal Balloon Mandibular splint Pedometers

EXERCISE Heart Failure COPD Cancer Fatigue Depression

PROCEDURES

Plantar stretch Epley for BPPV Wet combing Pelvic floor training APPS Quit Smoking CBT for Anxiety Insomnia

Many methodological problems to overcome

1. Devices: autoinflation for glue ear

Cochrane review, 2006

- Some small RCTs
- "Promising; inconclusive"

UK HTA-funded trial of 320 kids, 2015

• Effective (NNT=10)

	No. (%) of children*			
Variable	Standard care n = 160	Autoinflation $n = 160$		
1-month analysis	<i>n</i> = 132	<i>n</i> = 131		
Tympanometric resolution of ≥ 1 type-B ear per child at 1 mo‡	47 (35.6)	62 (47.3)		







Question 1: What is sufficient evidence? **Answer**: Usually 2+ randomized trials



2. Exercise – for chronic illnesses

CURRENT ENTRIES ✓ COPD ✓ Cancer fatigue ✓ Chronic Fatigue ✓ Claudication ✓ Heart Failure ✓ Depression

POSSIBLES

Anxiety



Committee presentations of possible entries

PAUL GLASZIOU, HANDI, NOVEMBER 2015

Exercise for Cancer Fatigue

References

1. Cramp F1, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012 Nov 14;11:CD006145.

2. Kampshoff CS et al. Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study. BMC Med. 2015;13:275.

Is there sufficient evidence?

Question 2: Which treatment to use? **Answer**: Consider treatments of single trials



Glasziou et al. Intervention synthesis: a missing link between a systematic review and practical treatment(s). PLoS Med. 2014

3. Procedures



Epley for BPPV

Pulled elbow manipulation

Stretches for plantar fasciitis

(Several randomized trials to support these)

Question 3: Are randomized trials <u>always</u> required? **Answer**: Not for some "dramatic" effects

The "Mother's Kiss" technique

Child with nasal foreign body

- Dislodged with Parent Kiss method
- Case series of success 15/19 (Botma J Laryngol Otol 2000)
- Systematic review of series

Cook SC, Burton DM & Glasziou P. Efficacy and safety of the "mother's kiss" technique: a systematic review of the case reports and case series. CMAJ 2012



When are randomised trials unnecessary? Picking signal from noise. Glasziou P, Chalmers I, Rawlins M, McCulloch P. BMJ. 2007;334:349-51.

4. Diet & Nutrition

✓ Mediterranean diet for CHD prevention

✓ Early introduction of peanuts to prevent allergy development

✓ FODMAP diet for Irritable Bowel Syndrome



Evidence: 2+ randomized trials Mediterranean Diet

- 1. Lyon Heart Study (Lancet, 1994) RCT showed lower mortality
- PREDIMED randomized trial: 7447 men & women 55-80 years of age without CV disease; type 2 diabetes mellitus or ≥ 3 major risk factors. (NEJM)









Mediterranean diet: reducing cardiovascular disease risk

In 2010, UNESCO officially recognised the Mediterranean diet pattern to be part of the cultural heritage of Italy, Greece, Spain and Morocco.

Intervention

Give feedback on this topic

A change in overall dietary pattern to increase intake of fresh fruits, vegetables, grains, nuts and fish and decrease intake of meat and dairy, known as the Mediterranean diet.

Total energy intake is adapted to meet individual needs. There is no specific fat restriction, as long as fat is mostly derived from fatty fish and plant sources (particularly olive oils or nuts). Patients view the Mediterranean diet as tastier and more filling than low-fat diets, which leads to increased long-term compliance.

Indication

Prevention of subsequent cardiovascular events in patients who have had myocardial infarction.

Description

The Mediterranean diet comprises:

- high monounsaturated (eg olive oil) to saturated (eg fatty red meat) ratio at least 2:1
- high intake of legumes
- high intake of fruits and vegetables
- · high intake of grains and cereals
- moderate quantities of fish, white meat and low-fat dairy
- · low to moderate consumption of red wine
- · low intake of red meat, processed meat and eggs
- · low intake of sweets, sweet desserts and sweet drinks.

Refer to the Consumer resources for food group portion guide.

Simple guidelines for implementing the MedDiet in clinical practice

- Assess adherence to a Mediterranean diet using the <u>PREDIMED 14-item Questionnaire</u>. This tool can also be used for monitoring changes at future clinical consultations
- · Introduce simple changes to the patient's diet, such as:
- using olive oil instead of other oils/ fats for cooking and dressing salads and cooked vegetables

Format similar to Drug Formulary

Handouts on "how to" as pdf

What is the "Mediterranean" Diet?

Requirements for delivering the diet

1. Compliance Score sheets

Table S1. Quantitative Score of Compliance with the Mediterranean Diet.

* 0 points if these criteria are not met.

	Foods and frequency of consumption	Criteria for 1 point*
1	Do you use <mark> olive oil</mark> as main culinary fat?	Yes
2	How much olive c ^{pglaszio} u consume in a given day (including oil used for frying, salads, out of house	4 or more tablespoons
	meals, etc.)?	
3	How many vegetable servings do you consume per day?	2 or more (at least 1 portion raw
	(1 serving = 200g - consider side dishes as 1/2 serving)	or as salad)
4	How many <mark>fruit</mark> units (including natural fruit juices) do you consume per day?	3 or more
5	How many servings of red meat, hamburger, or meat products (ham, sausage, etc.) do you	Less than 1
	consume per day? (1 serving = 100-150 g)	
6	How many servings of <mark>butter, margarine, or cream</mark> do you consume per day? (1 serving = 12 g)	Less than 1
_	· · · · · · · · · · · · · · · · · · ·	
7	How many sweet/carbonated beverages do you drink per day?	Less than 1
8	How much <mark>wine</mark> do you drink per week?	7 or more glasses
9	How many servings of legumes do you consume per week?	3 or more
	(1 serving = 150 g)	
10	How many servings of fish or shellfish do you consume per week?	3 or more
	(1 serving: 100-150 g fish, or 4-5 units or 200 g shellfish)	
11	How many times per week do you consume commercial sweets or pastries (not homemade), such	Less than 3
	as cakes, cookies, biscuits, or custard?	
12	How many servings of nuts (including peanuts) do you consume per week?	3 or more
	(1 serving = 30 g)	
13	Do you preferentially consume chicken, turkey or rabbit meat instead of veal, pork, hamburger or	Yes
	sausage?	
14	How many times per week do you consume vegetables, pasta, rice, or other dishes seasoned with	
	<mark>sofrito</mark> (sauce made with tomato and onion, leek, or garlic, simmered with olive oil)?	2 or more

2. PREDIMED materials Translated from Spanish



Inadequate treatment descriptions Analysis of 80 studies in EBM journal

"Could you use this treatment with a patient tomorrow?"



Glasziou P, et al. BMJ 2008;336:1472-74

Summary (so far)

Effective Non-Drug treatments

- many developed and tested in RCTs
- but the treatment is often poorly described
- little usage
- (Hence development of <u>www.racgp.org.au/handi</u>)





Going from research to patient benefits?

Questions relevant to clinicians & patients?

Low priority questions



Unbiased and usable report?

Over 30% of trial

Avoidable waste in the production and reporting of research evidence





Annual waste in research is estimated to be 85% - from avoidable design flaws (50%), non-publication (50%) and unusable reports (50%) – for a global total of over \$140 Billion/year.

http://blogs.bmj.com/bmj/2016/01/14/ paul-glasziou-and-iain-chalmers-is-85-of-health-research-really-wasted/





50% of research is not published But similar across countries, size, phase, ...



Lancet 2014; 383: 257-66

Non-Publication: a solution*



www.alltrials.net/

Monitoring "the solution" Automated tracking by institution **Who's not sharing their trial results?**

Trials registered on ClinicalTrials.gov should share results on the site shortly after completing, or publish in a journal. But many organisations fail to report the results of clinical trials. We think this should change. Explore our data (last updated October 2016) to see the universities, government bodies and pharmaceutical companies that aren't sharing their clinical trial results.

Trial sponsors

We've ranked the major trial sponsors with the most unreported trials registered on ClinicalTrials.gov. Click on a sponsor's name to find out whether it's getting better at reporting completed trials - or worse.

	Name of sponsor	Trials]; missing results	Total eligible trials	Percent missing	
1	Sanofi	285	435	65.5%	
2	Novartis Pharmaceuticals	201	534	37.6%	
3	National Cancer Institute (NCI)	194	558	34.8%	
4	Assistance Publique - Hôpitaux de Paris	186	292	63.7%	
5	GlaxoSmithKline	183	809	22.6%	
6	Mayo Clinic	157	312	50.3%	
7	Yonsei University	139	194	71.6%	
8	Seoul National University Hospital	131	207	63.3%	
9	Alliance for Clinical Trials in Oncology	129	160	80.6%	k

Trials by year

Since Jan 2006, **all major trial sponsors** completed 25,927 eligible trials and **haven't published results for 11,714 trials**. That means 45,2% of their trials are missing results.



https://trialstracker.ebmdatalab.net/#/





New research should build on previous research

Horn J et al. Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled **TRIAL**. Stroke. 2001 RESULTS: At trial termination, after inclusion of 454 patients (225 nimodipine, 229 placebo), **no effect** of nimodipine was found.

Horn J, et al. Calcium antagonists for acute ischemic stroke. The Cochrane Database of **SYSTEMATIC REVIEWS**. 2001. RESULTS "46 trials were identified of which 28 were included (7521 patients). <u>No effect</u> of calcium antagonists on poor outcome at the end of follow-up (OR 1.07), or on death at end of follow-up (OR 1.10) was found."

Horn J et al. Nimodipine in **ANIMAL** model experiments of focal cerebral ischemia: a **SYSTEMATIC REVIEW** Stroke. 2001 Oct. "20 studies ... review did not show convincing evidence to substantiate the decision to perform trials with nimodipine in large numbers of patients."

Animal systematic reviews & registry

 Federatie van medisch wetenschappelijke verenigingen
 Tedera
 COREON
 COREON

 Federa Bulletin
 COREON
 COREON
 COREON
 COREON

Too valuable to waste

Hoe verkwisten we zo weinig mogelijk waarde van dierproeven en klinische trials? Aanstaande vrijdag behandelen diverse sprekers deze vraag.

Registration

Meer waarde uit dierproeven halen

FederaPrijs voor dr. Janneke Horn, neuroloog-intensivist aan het AMC

Too valuable to waste: Experiments on humans and animals



Human clinical trials and animal experiments for medicine need a sound regulation. That is needed to get valid results and to avoid waste of efforts. However, meetings of clinical trial researchers with animal experiments researchers are taken place very rarely. The FederaDag 2017 will offer knowledge and connection to experts in both fields.

Friday June 16th, the FederaDag 2017 takes place at NWO in The Hague, and is organized by Federa in cooperation with ZonMw.



Reports of Randomized Trials are often missing essential methods



Chen & Altman, Lancet 2005; Hopewell BMJ 2010

What is the treatment?

The paper's description of sodium reduction

• "Individual and weekly group counseling sessions were offered initially, with less intensive counseling and support thereafter, specific to sodium reduction."

What would you tell a patient to do?



TOHP Study BMJ, Apr 2007; 334: 885

What is sodium reduction?



The BMJ paper's description

"Individual and weekly group counseling sessions were offered initially, with less intensive counseling and support thereafter, specific to sodium reduction."

Description in earlier (paywalled) reference:

1. an individual session followed by **10 weekly group 90 minute sessions** with a nutritionist, followed by a transitional stage of some additional sessions

2. Topics in the weekly sessions included Getting Started, sodium basics, the morning meal, midday sources of sodium, the main meal, planning ahead, creative cooking, eating out, food cues, and social support,

3. the sessions included **sampling** of foods, **discussion of articles** on sodium reduction, and problem-solving,

4. patients kept **diaries** at least 6 days per week, and **urine sodiums** were measured.

Poor descriptions of treatments



BMJ 2014;348:g1687 doi: 10.1136/bmj.g1687 (Published 6 March 2014)

Page 1 of 13

RESEARCH METHODS & REPORTING

Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide

Tammy C Hoffmann associate professor of clinical epidemiology¹, Paul P Glasziou director and professor of evidence based medicine¹, Isabelle Boutron professor of epidemiology⁷, Ruairidh Mine professorial tellow in public health and director³, Rafael Perera university lecturer in medical statistics⁴, David Moher senior scientist⁶, Douglas G Altman professor of statistics in medicine⁶, Virginia Barbour medicine editorial director, PLOS⁷, Helen Macdonald assistant editor⁶, Marie Johnston emeritus professor of health psychology⁹, Sarah E Lamb Kadoorie professor of trauma rehabilitation and co-director of Oxford clinical trials research unit¹⁰, Mary Dixon-Woods professor of medical sociology¹¹, Peter McCulloch clinical reader in surgery¹², Jeremy C Wyatt leadership chair of ehealth research¹³, An-Wen Chan Phelan scientist¹⁴, Susan Michie professor¹⁵

		-	
T			

BMI

The TIDieR (Template for Intervention Description and Replication) Checklist*:

Template for Information Information to include when describing an intervention and the location of the information

Item	Item	Where located **		
number		Primary paper (page or appendix number)	Other [†] (details	
1.	BRIEF NAME Provide the name or a phrase that describes the intervention.	_		
	WHY			
2.	Describe any rationale, theory, or goal of the elements essential to the intervention. WHAT			
3.	Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers.		-	
	Provide information on where the materials can be accessed (e.g. online appendix, URL).			
4.	Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities. WHO PROVIDED			
5.	For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given. HOW			
6.	Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group. WHERE			
7.	Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.			



• Effective NonDrug treatments:

many developed and tested, but poorly described and little used

• <u>www.racgp.org.au/handi</u>

• Avoidable Waste in Research:

over 85%, due to poor design, non-publication, and poor reporting

http://rewardalliance.net/





Light Therapy Current Utilisation (in <u>Austria</u>)

Winkler-Pirek E et al. Use of Light Therapy (LT) by Office-Based Physicians. Neuropsychobiology. 2016; 74(4):182-187

A questionnaire-survey of 400 randomly selected office-based doctors in Austria.

Results

Light Therapy (LT) recommended by 67% of physicians, 92% of psychiatrists & 47% of GPs.

The recommended location of treatment was patients' homes in 90%.

Physicians were asked whether they considered LT to be an appropriate treatment for various disorders - affirmative answers:

94% for seasonal affective disorder (SAD)
93% for sub-syndromal SAD
61% for non-seasonal recurrent major depressive disorder
36% for jet lag syndrome,
36% for chronobiological problems with shift work
22% for insomnia, 14% for premenstrual dysphoric disorder
11% for behavioural problems with Alzheimer's disease.